Incretin Hormones in Type 1 Diabetes Mellitus;Effect of Metformin Treatment (INCREDIBLE-M)
Gut-derived Incretin Hormones in the Pathophysiology of Type 1 Diabetes Mellitus; Effect of Metformin Treatment
Sponsor: Hellenic Institute for the Study of Sepsis
A PHASE3 clinical study on Type 1 Diabetes Mellitus, this trial is ongoing. The trial is conducted by Hellenic Institute for the Study of Sepsis and has accumulated 7 data snapshots since 2019. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Unknown PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Unknown PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE3
Status: Unknown Status → Unknown
-
Dec 2022 — Jul 2024 [monthly]
Unknown Status PHASE3
Status: Recruiting → Unknown Status
-
Jan 2021 — Dec 2022 [monthly]
Recruiting PHASE3
▶ Show 2 earlier versions
-
Mar 2020 — Jan 2021 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Dec 2019 — Mar 2020 [monthly]
Not Yet Recruiting PHASE3
First recorded
Nov 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Hellenic Institute for the Study of Sepsis
For direct contact, visit the study record on ClinicalTrials.gov .